In re Lamictal Direct Purchaser Antitrust Litigation

Brief of the Federal Trade Commission as amicus curiae before the United States District Court for the District of New Jersey, addressing the question of whether an exclusive license that effectively prevents a branded company from launching an authorized generic constitutes a payment-for-delay in restraint of trade, pursuant to the Third Circuit’s ruling in In re K-Dur Antitrust Litigation, No. 10-2077, 2012 WL 2877662 (3d Cir. July 16, 2012).